Finding out what helps patients with lung disease related to systemic sclerosis respond to treatment
Identifying predictors of treatment response in systemic sclerosis-related interstitial lung disease
This study is looking at how certain traits of people with systemic sclerosis-related lung disease can help doctors figure out who will respond best to common treatments, so they can personalize care and improve health outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10807119 on NIH RePORTER |
What this research studies
This research investigates how different clinical and biological characteristics of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) can predict their response to immunosuppressive therapies. By analyzing proteins in lung and blood samples, the study aims to identify which patients are likely to benefit from standard treatments like cyclophosphamide and mycophenolate, and which may need alternative therapies. The goal is to develop a precision medicine approach that tailors treatment based on individual patient profiles, improving outcomes for those affected by this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with systemic sclerosis who also have interstitial lung disease.
Not a fit: Patients without systemic sclerosis or those whose lung disease is unrelated to systemic sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with systemic sclerosis-related lung disease.
How similar studies have performed: Previous research has shown promise in identifying predictors of treatment response in similar conditions, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Volkmann, Elizabeth R — University of California Los Angeles
- Study coordinator: Volkmann, Elizabeth R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.